Elekta (OTCMKTS:EKTAY) Sets New 52-Week Low – Should You Sell?

Elekta AB (OTCMKTS:EKTAY) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $4.35 and last traded at $4.35, with a volume of 4237 shares. The stock had previously closed at $4.4530.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 16th. UBS Group started coverage on Elekta in a report on Wednesday, September 3rd. They set a “sell” rating on the stock. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Elekta currently has a consensus rating of “Reduce”.

Elekta Price Performance

The company has a quick ratio of 0.82, a current ratio of 1.05 and a debt-to-equity ratio of 0.63. The stock’s 50-day moving average is $5.02 and its 200-day moving average is $5.03. The firm has a market cap of $1.60 billion, a P/E ratio of 72.51 and a beta of 1.12.

Elekta (OTCMKTS:EKTAY) last posted its quarterly earnings data on Thursday, August 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The company had revenue of $379.64 million for the quarter. Elekta had a net margin of 1.40% and a return on equity of 11.49%. As a group, equities analysts anticipate that Elekta AB will post 0.36 EPS for the current fiscal year.

Elekta Dividend Announcement

The company also recently declared a dividend, which was paid on Friday, September 26th. Shareholders of record on Tuesday, September 9th were issued a $0.0744 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a yield of 289.0%. Elekta’s dividend payout ratio is 200.00%.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.